CYH33 + dapagliflozin
CYH33 + dapagliflozin has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Oct 17, 2026: “Dapagliflozin alleviates CYH33-induced hyperglycemia and preserves antitumor immunity against ovarian cancer in type 1 diabetic mice”.
None of its findings points the other way.
- 1 lab in 1 country
- Animals1
What did studies of CYH33 + dapagliflozin find?
2Studies of CYH33 + dapagliflozin measured 2 outcomes; the most studied are antitumor efficacy (1 study) and CD8+ T cell infiltration (1).
Antitumor efficacy
upin mice1
1 study
Antitumor efficacy
upin mice1
CYH33 + dapagliflozin improves antitumor efficacy in mice.
“Furthermore, this combination synergized with anti-PD-1 antibody to further enhance antitumor efficacy.”
AnimalsCYH33 and dapagliflozin combined with anti-PD-1 antibody
Life sciences
CD8+ T cell infiltration
upin mice1
1 study
CD8+ T cell infiltration
upin mice1
CYH33 + dapagliflozin increases CD8+ T cell infiltration in mice.
“significantly enhanced infiltration of CD8+ T-cell in ID8 tumors.”
Animalstype 1 diabetesID8 tumor
Life sciences